Major Drug Interaction

Can You Take Celecoxib with METHOCARBAMOL?

A plain-English look at the major interaction between Celecoxib (Celebrex) and METHOCARBAMOL (Methocarbamol) — what it means, why it happens, and what to talk to your doctor or pharmacist about.

Reviewed by , Registered Pharmacist
Last reviewed: How we research and review
Major severity AllMeds interaction database

Taking Celecoxib (Celebrex) with METHOCARBAMOL (Methocarbamol) is a major drug interaction that should be avoided. Excessive sedation, respiratory depression, falls. Additive CNS depression. Both classes cause sedation and respiratory depression through complementary pathways.

Not sure about your specific combination? Check it in the Drug Interaction Checker →

Key Takeaways

  • Interaction severity: Major
  • Risk: Excessive sedation, respiratory depression, falls.
  • Mechanism: Additive CNS depression. Both classes cause sedation and respiratory depression through complementary pathways.
  • Celecoxib: S4 in Australia, low risk
  • METHOCARBAMOL: S4 in Australia, low risk
  • Claims action: Flag for immediate prescriber review. Document intervention in claim file.

Celecoxib vs METHOCARBAMOL at a Glance

Property Celecoxib METHOCARBAMOL
Brand names Celebrex, Celecoxib Sandoz, Celecoxib GH Methocarbamol
Drug class opioid muscle relaxant
Risk level low low
TGA Schedule (AU) S4 S4

Why Is This Combination Dangerous?

Additive CNS depression. Both classes cause sedation and respiratory depression through complementary pathways.

Clinical risk: Excessive sedation, respiratory depression, falls.

Regulatory Guidance by Jurisdiction

Australia TGA / SIRA / WorkSafe

The TGA and Australian Medicines Handbook classify this as a major drug interaction requiring immediate intervention.

United Kingdom NICE / MHRA / FPM

UK clinical guidelines recommend caution with this combination. For personal injury claims, the prescribing rationale should be documented and reviewed against NICE and FPM guidance.

United States FDA / CDC / State WC

The CDC and FDA recommend monitoring concurrent CNS depressant use. State workers compensation formularies may restrict or require prior authorization for this combination.

What Claims Professionals Should Do

  1. Flag immediately as a high-risk prescribing pattern in the claim file
  2. Request urgent prescriber review with documented clinical justification for the combination
  3. Consider an independent medical examination if the prescriber cannot provide adequate justification
  4. Assess work capacity impact as the combination significantly increases sedation and impairment risk
  5. Document all interventions for audit trail and compliance purposes
  6. Check Reasonable and Necessary status for both medications against the compensable injury

Clinical reference

Informational Theoretical

A clinical summary of Celecoxib and METHOCARBAMOL drawn from regulator advisories, national guidelines, and authoritative drug references. Read this if you want the deeper clinical picture before talking to your prescriber or pharmacist.

Severity assessment

Informational. While no direct interaction is documented, there is a theoretical risk of additive central nervous system (CNS) depression due to the known effects of methocarbamol.

Mechanism (plain English)

Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that works by reducing inflammation and pain in the body. Methocarbamol is a muscle relaxant that acts on the central nervous system to relieve muscle spasms. Individually, methocarbamol can cause drowsiness and dizziness due to its CNS depressant effects. Although there is no direct pharmacokinetic (how the body handles the drug) or pharmacodynamic (how the drug affects the body) interaction specifically identified between celecoxib and methocarbamol, combining them could potentially lead to increased sedative effects, as some NSAIDs can also cause dizziness or drowsiness as side effects.

Evidence level

Theoretical. No specific regulator-flagged or guideline-supported interaction has been identified for this exact drug pair. The assessment is based on the known pharmacological profiles of each drug, particularly the CNS depressant effects of methocarbamol, as noted in its prescribing information.

Top regulator advisories (cite verbatim or close paraphrase)

  • TGA (Australia): No pair-specific public advisory found. For celecoxib, the Australian Product Information (PI) would generally contain warnings common to NSAIDs regarding cardiovascular and gastrointestinal risks, but not specific interactions with muscle relaxants like methocarbamol. For methocarbamol, the PI would advise caution with other CNS depressants.
  • MHRA / NICE (UK): No specific guidance from MHRA or NICE found for this combination. The British National Formulary (BNF) would likely advise caution with methocarbamol due to its sedative properties when co-administered with other CNS depressants.
  • FDA / CDC (US): No specific FDA label or safety communication directly addresses an interaction between celecoxib and methocarbamol. The FDA-approved label for methocarbamol states: "Since methocarbamol may possess a general CNS depressant effect, patients receiving Methocarbamol tablets, USP should be cautioned about combined effects with alcohol and other CNS depressants." [DailyMed - METHOCARBAMOL tablet, coated METHOCARBAMOL tablet, 2026] The FDA label for celecoxib (Celebrex) does not list methocarbamol or general muscle relaxants as specific interacting drugs, but includes general warnings for NSAIDs.
  • EMA (Europe): No specific EMA advisory found for this combination.

Clinical risk factors that elevate the danger

  • Concomitant use of other CNS depressants: Including alcohol, opioids, benzodiazepines, or other sedating medications, which can exacerbate drowsiness and dizziness.
  • Elderly patients: More susceptible to CNS depressant effects and their consequences, such as falls.
  • Patients with impaired hepatic or renal function: May have altered metabolism or excretion of either drug, leading to increased drug levels and side effects.
  • Operating machinery or driving: Increased risk of accidents due to impaired alertness.

What a patient should be told

  • You might feel more drowsy or dizzy than usual when taking celecoxib and methocarbamol together. Be careful when standing up or moving around.
  • Do not drive or operate heavy machinery until you know how this combination affects you.
  • Avoid alcohol and other medications that can make you sleepy, as this can worsen drowsiness.
  • If you experience excessive sleepiness, confusion, or difficulty breathing, seek urgent medical attention.
  • Always discuss all your medications, including over-the-counter drugs and supplements, with your doctor or pharmacist to ensure safe use and explore safer alternatives if needed.

Top 3 sources (with full citation)

  1. Drugs.com. Celebrex + Methocarbamol: Can You Take Them Together? https://www.drugs.com/drug-interactions/celebrex-with-methocarbamol-560-284-1588-0.html
  2. DailyMed. METHOCARBAMOL tablet, coated METHOCARBAMOL tablet. National Library of Medicine. Updated January 8, 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=31508051-c9cb-149b-e054-00144ff88e88
  3. U.S. Food and Drug Administration. CELEBREX® (celecoxib) capsules, for oral use. Revised: 11/2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020998s058lbl.pdf

Notes for the reviewing pharmacist

This interaction is primarily theoretical, based on the potential for additive CNS depressant effects rather than a direct, documented pharmacokinetic or pharmacodynamic interaction between celecoxib and methocarbamol. Clinical vigilance for increased sedation, dizziness, or impaired psychomotor function is warranted, especially in vulnerable populations (e.g., elderly) or those on other CNS depressants. Patient counseling should focus on symptomatic awareness and safety precautions, such as avoiding driving or operating heavy machinery. No specific regulatory advisories or guidelines were found for this exact combination, suggesting it is not considered a major interaction requiring specific management protocols beyond general caution for CNS depressants. The FDA label for celecoxib does not list methocarbamol as an interacting drug, and the methocarbamol label broadly warns against concomitant use with other CNS depressants. This aligns with the theoretical assessment of additive CNS depression. It is important to emphasize that while no specific interaction is flagged, the general CNS depressant properties of methocarbamol necessitate caution when combined with any medication that could also cause sedation or dizziness, even if not a direct drug-drug interaction in the classical sense.

Source metadata JSON

Sources used in this brief (3)

Check this medication against your full medication list

Check all interactions for Celecoxib and METHOCARBAMOL across your claimant's full medication list.

Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.

Try it free → Talk to Sales →

Related Resources

Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.